Vendor dossier · Guangzhou, Guangdong
Guangzhou JEEP Biotechnology Co., Ltd.
A Guangzhou factory-direct operation with the best analytical record in this directory and no independent corporate record we have been able to find.
Journal grade · ranked 11 of 20
722 reader reports
on the record
The material we have bought from JEEP has tested better, more consistently, than anything else in this directory. Twelve independent purity determinations, mean 98.7%, no result below 97.9%. We have also been unable to locate an incorporation record, a registered address that resolves to a facility, or any trade record predating 2022. Both of those sentences are findings and neither cancels the other.
Storefront The company sells directly at jeepbio.com. Visit JEEP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Twelve independent purity determinations, mean 98.7%, range 97.9–99.5%. Two peptide content determinations, both within 2% of label. Two mass-spectrometric identity confirmations, both matching calculated monoisotopic mass to within 0.4 Da. On the analytical evidence this is the strongest record we hold on any vendor.
On the corporate side we have very little. The company describes itself as factory-direct with a GLP-1 specialty. We asked for a registered entity name and an incorporation number on four occasions and received a trading name and a Guangzhou district. A freight agent we use was unable to confirm that the collection address corresponds to a manufacturing facility rather than a consolidation warehouse.
We are reporting this the way we would report it about anyone: the product record is excellent, the corporate record is thin, and a reader deciding what to do with that has more information than they would have from a rating alone. It is also worth saying plainly that thin corporate documentation is the norm in this market, not the exception — JEEP is unusual for its results, not for its opacity.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Twelve independent purity determinations, mean 98.7% (range 97.9–99.5%) — the strongest record in this directory.
- Two peptide content determinations by nitrogen, both within 2% of label.
- Two LC-MS identity confirmations, both matching calculated monoisotopic mass within 0.4 Da.
- Twelve of twelve orders delivered; median transit nine days; cold packs intact on 11 of 12.
What we could not verify
- Registered entity name and incorporation number. Four written requests; a trading name and a district in reply.
- That the collection address is a manufacturing facility rather than a consolidation warehouse — our freight agent could not confirm either way.
- Any trade record predating 2022.
- Sterility and endotoxin. Not offered.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-06 | Medutest | Liraglutide 15 mg | 99.6% | 98.5% | 98% |
| 2026-05 | PeptideMeter | Tesamorelin 20 mg | 99.1% | 97.9% | not tested |
| 2026-01 | PeptideMeter | Cagrilintide 20 mg | 97.1% | 96.6% | not tested |
| 2025-12 | PeptideMeter | Survodutide 2 mg | 96.7% | 96.4% | not tested |
| 2025-11 | Medutest | Cagrilintide 15 mg | 96.6% | 96.4% | not tested |
| 2025-09 | PeptideMeter | Liraglutide 15 mg | 99.5% | 98.5% | not tested |
| 2025-08 | Janoshik | Tesamorelin 15 mg | 97.7% | 96.5% | not tested |
| 2025-04 | VendorInvestigate | Survodutide 20 mg | 97.2% | 96.6% | not tested |
| 2025-02 | VendorInvestigate | Survodutide 10 mg | 99.2% | 98.2% | 89% |
| 2025-02 | VendorInvestigate | Liraglutide 2 mg | 98.3% | 97.3% | not tested |
| 2025-01 | PeptideMeter | Tesamorelin 2 mg | 97.4% | 96.4% | not tested |
| 2024-01 | Janoshik | Tesamorelin 5 mg | 98.8% | 98.3% | not tested |
| 2024-01 | Medutest | Retatrutide 20 mg | 96.7% | 96.0% | 81% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 1 of 8 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Asked whether sterility or endotoxin testing is performed | Acknowledged; no substantive reply |
| 2026-05 | Asked whether release testing is performed per lot or per campaign | Declined as commercially confidential |
| 2026-03 | Requested confirmation of the registered entity name and incorporation number | Declined as commercially confidential |
| 2025-09 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days |
| 2025-07 | Asked whether corrected certificates are reissued to earlier purchasers | No response after two follow-ups |
| 2025-06 | Requested the reference-standard lot number | Answered in part; the specific question was not addressed |
| 2025-04 | Requested comment on an independent purity determination below the stated figure | Offered a video call in place of a written answer; declined |
| 2025-02 | Asked whether pre-change stock remained in distribution | Offered a video call in place of a written answer; declined |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Held locally in Canada, so the tirzepatide 15 mg arrived on day 5 without an import step.
Ordered epithalon 10 mg twice. Both vials reconstituted cleanly and both matched their certificates.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.
Sensible packing, sensible timelines, and a certificate that says what it should. No notes.
Solid on the tirzepatide 10 mg. Purity where it should be, transit 3 days, paperwork in order.
Documentation is complete and the numbers are steady. A dependable choice for routine work.
Moved here after two bad lots elsewhere. 6 orders in and the PeptideMeter numbers have been flat every single time.
Every certificate I have from them is lot-specific. Not one batch-level document in 4 orders.
Queried the related-substances total on lot JEE-24-658; they came back with method, column and detection limit. That depth is rare.
Costed them per mg against three other suppliers on the same GHRP-2 5 mg spec. Competitive on price and clearly ahead on documentation.
Arrived on day 4 against a quoted 4. Customs paperwork was right first time, which is why it moved that fast.
Janoshik has now seen 7 of their lots through me. Not one has come back outside spec.
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
Everything about the order was routine in the best sense — quoted 3 days, arrived in 3.
Third order and it went the same way as the first two. Predictable in the way you want a supplier to be.
8 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
Cold pack was still hard on arrival in Ottawa on day 4. My logger never went above 6°C across the whole run.
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
Same lot documentation as the factory ships, but out of their warehouse in Canada, so it landed on day 2.
Regional stock makes the difference — dispatched within the Netherlands, day 5, cold pack still hard on arrival.
Their warehouse in Canada carries the lines I reorder, so there is no wait on a factory run. Day 3 every time.
Quoted 5 days, arrived in 4. Tracking updated at every hop from dispatch to door.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 7 hours.
Domestic dispatch from their stock in the United Kingdom. Straightforward, day 3, exactly as quoted.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from jeepbio.com. Visit JEEP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Guangzhou JEEP Biotechnology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.